drugset / Trial / NCT03403556
High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe compared to high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes
Timeline
- Start
- 2018-03-27
- Primary completion
- 2021-10
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ezetimibe | Unknown | 10 mg | — |
| Subject | Rosuvastatin | Small molecule | 10 mg | — |
| Subject | Rosuvastatin | Small molecule | 20 mg | — |